SEC Form 4 · accession 0001127602-17-008730
GILEAD SCIENCES, INC. · GILD
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Gayle E Wilson
Director
Period of report
Feb 23, 2017
Accepted (ET)
Feb 27, 2017 · 6:29 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000882095
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Feb 23, 2017 | M | 33,350 | $20.705 | A | 140,836 | D | |
| Common StockF1 | Feb 23, 2017 | S | 20,365 | $69.3039 | D | 120,471 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Non-qualified Stock Option (Right to Buy)F2 | $20.705 | Feb 23, 2017 | M | 33,350 | D | — | May 9, 2017 | Common Stock | 33,350 | 0 | D |
Explanation of responses
- F1Sale prices reported for the transactions reported here range from $69.281 to $69.331. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request.
- F2Options are 100% vested on the date of grant.